Journal of Gastrointestinal Cancer

, Volume 50, Issue 4, pp 709–715 | Cite as

Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience

  • Satya DasEmail author
  • Chanjuan Shi
  • Liping Du
  • Kamran Idrees
  • Jordan Berlin
Original Research



Adenocarcinoma ex-goblet cell carcinoids (AGCCs) are rare appendiceal tumors with mixed neuroendocrine and glandular features. They tend to behave more aggressively than typical carcinoid tumors, affect younger patients, and have a greater predilection for spreading to the peritoneum. Outcomes of AGCC patients treated with chemotherapy, extrapolated from colon cancer regimens, in the adjuvant or metastatic setting have not been explicitly reported. We sought to explore outcomes of AGCC patients with either local disease treated with adjuvant FOLFOX or metastatic disease treated with FOLFOX/FOLFIRI post-cytoreductive debulking (or CRS plus HIPEC in the peritoneal-limited setting).


We performed a single-institution retrospective analysis of 23 pathologically identified AGCC patients from Vanderbilt University Medical Center treated with chemotherapy in either the adjuvant or metastatic settings. Each patient’s tumor was categorized as group B or group C based on the criteria from Tang et al. Median progression-free survival (PFS) or disease-free survival (DFS) (in the curative setting) and overall survival (OS) were determined for each patient and specified patient subgroup.

Results and Conclusion

AGCC patients who were treated with FOLFOX chemotherapy in the adjuvant setting or FOLFOX/FOLFIRI in the metastatic setting experienced prolonged PFS, DFS, and OS. Five patients with peritoneal-limited disease treated with CRS plus HIPEC have not yet reached median PFS or OS. While small sample size, patient selection, and retrospective nature limit the generalizability of findings from our analysis, the efficacy signals we observed suggest prospective evaluation with chemotherapy and CRS plus HIPEC is warranted in AGCC patients.


Adenocarcinoma ex-goblet cell Appendiceal tumor Chemotherapy HIPEC 


Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Piao J, Veerapong J, Li X, et al. Adenocarcinoma ex goblet cell carcinoid (GCC) of the appendix: report of five cases and pitfalls in diagnosis of GCC. Arch Surg Oncol. 2016;2:108.CrossRefGoogle Scholar
  2. 2.
    Tang L, Shia J, Soslow R, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32(10):1429–43.CrossRefGoogle Scholar
  3. 3.
    Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med. 2015;139:782–90.CrossRefGoogle Scholar
  4. 4.
    Tejani MA, Ter Veer A, Milne D, et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Cancer Netw. 2014;12(8):1123–30.CrossRefGoogle Scholar
  5. 5.
    Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, di Bartolomeo M, Ricchini F, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist. 2014;19(8):845–50.CrossRefGoogle Scholar
  6. 6.
    Goldberg R. Therapy for metastatic colorectal cancer. Oncologist. 2006;11(9):981–7.CrossRefGoogle Scholar
  7. 7.
    Reid M, Basturk O, Shaib W, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Mod Pathol. 2016;29(10):1243–53.CrossRefGoogle Scholar
  8. 8.
    Hristov AC, Young RH, Vang R, Yemelyanova AV, Seidman JD, Ronnett BM. Ovarian metastases of appendiceal tumors with goblet cell carcinoidlike and signet ring cell patterns: a report of 30 cases. Am J Surg Pathol. 2007;31:1502–11.CrossRefGoogle Scholar
  9. 9.
    McConnell Y, Mack L, Car N, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix. Ann Surg Oncol. 2014;21(6):1975–82.CrossRefGoogle Scholar
  10. 10.
    Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg. 2004;91:1168–73.CrossRefGoogle Scholar
  11. 11.
    Cashin P, Nygren P, Hellman P, Granberg D, Andréasson H, Mahteme H. Appendiceal adenocarcinoids with peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy: a retrospective study of in vitro drug sensitivity and survival. Clin Colorectal Cancer. 2011;10(2):108–12.CrossRefGoogle Scholar
  12. 12.
    Borazanci E, Millis S, Kimbrough J, et al. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J Gastrointest Oncol. 2017;8(1):164–72.CrossRefGoogle Scholar
  13. 13.
    Shenoy S. Goblet cell carcinoids of the appendix: tumor biology, mutations and management strategies. World J Gastrointest Surg. 2016;8(10):660–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Satya Das
    • 1
    Email author
  • Chanjuan Shi
    • 2
  • Liping Du
    • 3
  • Kamran Idrees
    • 1
  • Jordan Berlin
    • 1
  1. 1.Division of Hematology Oncology, Department of MedicineVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of PathologyVanderbilt University Medical CenterNashvilleUSA
  3. 3.Department of BiostatisticsVanderbilt Center for Quantitative SciencesNashvilleUSA

Personalised recommendations